Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up

Tohru Nakagawa, Masahiro Kami, Akiko Hori, Sung Won Kim, Naoko Murashige, Tamae Hamaki, Yukiko Kishi, Hiroyuki Fujimoto, Naoki Matsuoka, Eijiro Okajima, Motokiyo Komiyama, Ken Ichi Tobisu, Toshio Wakayama, Naokuni Uike, Kinuko Tajima, Atsushi Makimoto, Shinichiro Mori, Ryuji Tanosaki, Yoichi Takaue, Tadao Kakizoe

Research output: Contribution to journalArticle

37 Citations (Scopus)

Abstract

Objective The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen (RIST) for interferon-α-refractory metastatic renal cell carcinoma (RCC). Patients and methods Of 26 patients referred to the National Cancer Center Hospital for possible RIST between June 2000 and April 2002, an HLA-identical relative was identified for 12 patients. Nine patients underwent RIST. The conditioning regimen consisted of fludarabine 180 mg/m 2 or cladribine 0.66 mg/kg, plus busulfan 8 mg/kg and rabbit antithymocyte globulin 5 mg/kg. Graft-vs-host disease (GVHD) prophylaxis was cyclosporine alone. Results All patients achieved engraftment without grade III to IV nonhematologic regimen-related toxicity. All patients achieved complete donor-type chimerism without donor lymphocyte infusion by day 60. Four patients developed acute GVHD, and four developed chronic GVHD. One patient (11%) achieved partial response. As of July 2003, six patients were alive at median follow-up of 681 days. The actuarial overall survival rate was 89% at 1 year and 74% at 2 years. The overall survival rate tended to be higher in the 12 patients with a matched donor than in the other 14 patients without a matched donor (p=0.088). Conclusion Our RIST procedure is feasible without severe toxicity. The efficacy of RIST for RCC should be confirmed in phase II/III clinical trials.

Original languageEnglish
Pages (from-to)599-606
Number of pages8
JournalExperimental Hematology
Volume32
Issue number7
DOIs
Publication statusPublished - 2004 Jul
Externally publishedYes

Fingerprint

Hematopoietic Stem Cell Transplantation
Renal Cell Carcinoma
Graft vs Host Disease
Tissue Donors
Therapeutics
Survival Rate
Cladribine
Cancer Care Facilities
Busulfan
Phase III Clinical Trials
Phase II Clinical Trials
Chimerism
Antilymphocyte Serum
Interferons
Cyclosporine
Lymphocytes
Rabbits
Safety

ASJC Scopus subject areas

  • Cancer Research
  • Cell Biology
  • Genetics
  • Hematology
  • Oncology
  • Transplantation

Cite this

Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma : Single institution experience with a minimum 1-year follow-up. / Nakagawa, Tohru; Kami, Masahiro; Hori, Akiko; Kim, Sung Won; Murashige, Naoko; Hamaki, Tamae; Kishi, Yukiko; Fujimoto, Hiroyuki; Matsuoka, Naoki; Okajima, Eijiro; Komiyama, Motokiyo; Tobisu, Ken Ichi; Wakayama, Toshio; Uike, Naokuni; Tajima, Kinuko; Makimoto, Atsushi; Mori, Shinichiro; Tanosaki, Ryuji; Takaue, Yoichi; Kakizoe, Tadao.

In: Experimental Hematology, Vol. 32, No. 7, 07.2004, p. 599-606.

Research output: Contribution to journalArticle

Nakagawa, T, Kami, M, Hori, A, Kim, SW, Murashige, N, Hamaki, T, Kishi, Y, Fujimoto, H, Matsuoka, N, Okajima, E, Komiyama, M, Tobisu, KI, Wakayama, T, Uike, N, Tajima, K, Makimoto, A, Mori, S, Tanosaki, R, Takaue, Y & Kakizoe, T 2004, 'Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up', Experimental Hematology, vol. 32, no. 7, pp. 599-606. https://doi.org/10.1016/j.exphem.2004.04.006
Nakagawa, Tohru ; Kami, Masahiro ; Hori, Akiko ; Kim, Sung Won ; Murashige, Naoko ; Hamaki, Tamae ; Kishi, Yukiko ; Fujimoto, Hiroyuki ; Matsuoka, Naoki ; Okajima, Eijiro ; Komiyama, Motokiyo ; Tobisu, Ken Ichi ; Wakayama, Toshio ; Uike, Naokuni ; Tajima, Kinuko ; Makimoto, Atsushi ; Mori, Shinichiro ; Tanosaki, Ryuji ; Takaue, Yoichi ; Kakizoe, Tadao. / Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma : Single institution experience with a minimum 1-year follow-up. In: Experimental Hematology. 2004 ; Vol. 32, No. 7. pp. 599-606.
@article{344d517107c3490c9f5a40f2644a514a,
title = "Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma: Single institution experience with a minimum 1-year follow-up",
abstract = "Objective The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen (RIST) for interferon-α-refractory metastatic renal cell carcinoma (RCC). Patients and methods Of 26 patients referred to the National Cancer Center Hospital for possible RIST between June 2000 and April 2002, an HLA-identical relative was identified for 12 patients. Nine patients underwent RIST. The conditioning regimen consisted of fludarabine 180 mg/m 2 or cladribine 0.66 mg/kg, plus busulfan 8 mg/kg and rabbit antithymocyte globulin 5 mg/kg. Graft-vs-host disease (GVHD) prophylaxis was cyclosporine alone. Results All patients achieved engraftment without grade III to IV nonhematologic regimen-related toxicity. All patients achieved complete donor-type chimerism without donor lymphocyte infusion by day 60. Four patients developed acute GVHD, and four developed chronic GVHD. One patient (11{\%}) achieved partial response. As of July 2003, six patients were alive at median follow-up of 681 days. The actuarial overall survival rate was 89{\%} at 1 year and 74{\%} at 2 years. The overall survival rate tended to be higher in the 12 patients with a matched donor than in the other 14 patients without a matched donor (p=0.088). Conclusion Our RIST procedure is feasible without severe toxicity. The efficacy of RIST for RCC should be confirmed in phase II/III clinical trials.",
author = "Tohru Nakagawa and Masahiro Kami and Akiko Hori and Kim, {Sung Won} and Naoko Murashige and Tamae Hamaki and Yukiko Kishi and Hiroyuki Fujimoto and Naoki Matsuoka and Eijiro Okajima and Motokiyo Komiyama and Tobisu, {Ken Ichi} and Toshio Wakayama and Naokuni Uike and Kinuko Tajima and Atsushi Makimoto and Shinichiro Mori and Ryuji Tanosaki and Yoichi Takaue and Tadao Kakizoe",
year = "2004",
month = "7",
doi = "10.1016/j.exphem.2004.04.006",
language = "English",
volume = "32",
pages = "599--606",
journal = "Experimental Hematology",
issn = "0301-472X",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen for treatment of metastatic renal cell carcinoma

T2 - Single institution experience with a minimum 1-year follow-up

AU - Nakagawa, Tohru

AU - Kami, Masahiro

AU - Hori, Akiko

AU - Kim, Sung Won

AU - Murashige, Naoko

AU - Hamaki, Tamae

AU - Kishi, Yukiko

AU - Fujimoto, Hiroyuki

AU - Matsuoka, Naoki

AU - Okajima, Eijiro

AU - Komiyama, Motokiyo

AU - Tobisu, Ken Ichi

AU - Wakayama, Toshio

AU - Uike, Naokuni

AU - Tajima, Kinuko

AU - Makimoto, Atsushi

AU - Mori, Shinichiro

AU - Tanosaki, Ryuji

AU - Takaue, Yoichi

AU - Kakizoe, Tadao

PY - 2004/7

Y1 - 2004/7

N2 - Objective The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen (RIST) for interferon-α-refractory metastatic renal cell carcinoma (RCC). Patients and methods Of 26 patients referred to the National Cancer Center Hospital for possible RIST between June 2000 and April 2002, an HLA-identical relative was identified for 12 patients. Nine patients underwent RIST. The conditioning regimen consisted of fludarabine 180 mg/m 2 or cladribine 0.66 mg/kg, plus busulfan 8 mg/kg and rabbit antithymocyte globulin 5 mg/kg. Graft-vs-host disease (GVHD) prophylaxis was cyclosporine alone. Results All patients achieved engraftment without grade III to IV nonhematologic regimen-related toxicity. All patients achieved complete donor-type chimerism without donor lymphocyte infusion by day 60. Four patients developed acute GVHD, and four developed chronic GVHD. One patient (11%) achieved partial response. As of July 2003, six patients were alive at median follow-up of 681 days. The actuarial overall survival rate was 89% at 1 year and 74% at 2 years. The overall survival rate tended to be higher in the 12 patients with a matched donor than in the other 14 patients without a matched donor (p=0.088). Conclusion Our RIST procedure is feasible without severe toxicity. The efficacy of RIST for RCC should be confirmed in phase II/III clinical trials.

AB - Objective The aim of this study was to evaluate the safety and efficacy of allogeneic hematopoietic stem cell transplantation with a reduced-intensity conditioning regimen (RIST) for interferon-α-refractory metastatic renal cell carcinoma (RCC). Patients and methods Of 26 patients referred to the National Cancer Center Hospital for possible RIST between June 2000 and April 2002, an HLA-identical relative was identified for 12 patients. Nine patients underwent RIST. The conditioning regimen consisted of fludarabine 180 mg/m 2 or cladribine 0.66 mg/kg, plus busulfan 8 mg/kg and rabbit antithymocyte globulin 5 mg/kg. Graft-vs-host disease (GVHD) prophylaxis was cyclosporine alone. Results All patients achieved engraftment without grade III to IV nonhematologic regimen-related toxicity. All patients achieved complete donor-type chimerism without donor lymphocyte infusion by day 60. Four patients developed acute GVHD, and four developed chronic GVHD. One patient (11%) achieved partial response. As of July 2003, six patients were alive at median follow-up of 681 days. The actuarial overall survival rate was 89% at 1 year and 74% at 2 years. The overall survival rate tended to be higher in the 12 patients with a matched donor than in the other 14 patients without a matched donor (p=0.088). Conclusion Our RIST procedure is feasible without severe toxicity. The efficacy of RIST for RCC should be confirmed in phase II/III clinical trials.

UR - http://www.scopus.com/inward/record.url?scp=3042790638&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=3042790638&partnerID=8YFLogxK

U2 - 10.1016/j.exphem.2004.04.006

DO - 10.1016/j.exphem.2004.04.006

M3 - Article

C2 - 15246155

AN - SCOPUS:3042790638

VL - 32

SP - 599

EP - 606

JO - Experimental Hematology

JF - Experimental Hematology

SN - 0301-472X

IS - 7

ER -